ISTH 2021 Congress
Platelet Disorders, von Willebrand Disease and Thrombotic Microangiopathies » Platelet Antagonists and Novel Therapeutics
Theme Navigation
- ISTH 2021 Congress
- Platelet Disorders, von Willebrand Disease and Thrombotic Microangiopathies
- Platelet Antagonists and Novel Therapeutics
- Platelet Disorders, von Willebrand Disease and Thrombotic Microangiopathies
-
Abstract Number: PB0880
A Novel Dual AntiPlatelet and AntiCoagulant APAC: Interaction Between Platelet Factor 4 (PF4) and APAC Decreases Functional Activity
-
Abstract Number: OC 72.3
Assessing the Pharmacodynamics of RUC-4 (Zalunfiban), a Novel αIIbβ3 Antagonist, Using VerifyNow Assays in Patients with ST-Segment Elevation Myocardial Infarction (STEMI) Treated with Aspirin and Ticagrelor
-
Abstract Number: PB0878
Development of a Novel “Arterial Thrombosis-on-a-chip” Microfluidic Device
-
Abstract Number: PB0882
Lyophilized Human Platelets Support Thrombosis Unlike Normal Platelets in the Presence of GPIIb/IIIa Antagonists